Lantheus Holding Stock Price, News & Analysis

Lantheus Holdings (NASDAQ: LNTH), a leading radiopharmaceutical company, announced that CEO Brian Markison will present at the 2025 Truist Securities MedTech Conference on Tuesday, June 17 at 8:40 a.m. ET. The presentation will be accessible via live webcast through the Investors section of Lantheus's website at www.lantheus.com. A replay will remain available on the company's website for a minimum of 30 days after the live presentation.

Lantheus Holdings (NASDAQ: LNTH), a leading radiopharmaceutical company, announced that CEO Brian Markison will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025. The presentation is scheduled for Tuesday, June 10, at 2:40 p.m. ET. Investors and interested parties can access the live webcast through the Investors section of Lantheus's website at www.lantheus.com. A replay of the presentation will remain available on the company's website for a minimum of 30 days after the live event.

PharmaLogic Holdings Corp. has appointed Etienne Montagut as its new President and Chief Executive Officer, effective June 1, 2025. Montagut, who previously served as President, brings over 25 years of senior leadership experience in the pharmaceutical industry, with previous executive roles at Lantheus, GE HealthCare, and Ipsen. He succeeds Steve Chilinski, who retired after leading the company through 13 years of growth and will transition to Executive Chairman of the Board. The leadership change positions PharmaLogic, a leading radiopharmaceutical CDMO, to continue its expansion in novel diagnostics and therapies development.

Lantheus Holdings (NASDAQ: LNTH) reported Q1 2025 financial results with worldwide revenue of $372.8M, up 0.8% YoY. GAAP earnings per share decreased to $1.02 from $1.87, while adjusted EPS fell to $1.53 from $1.69. Key product performance included PYLARIFY sales of $257.7M (-0.5%) and DEFINITY sales of $79.2M (+3.5%). The company's cash position strengthened to $938.5M. Lantheus announced significant strategic moves: completing the Evergreen Theragnostics acquisition, expecting to close Life Molecular Imaging acquisition soon, and planning to divest its SPECT business. The company reported positive data for MK-6240 pivotal studies and plans an NDA filing in Q3 2025. However, the Phase 3 SPLASH study showed confounded results, leading to discontinued pursuit of the PNT2002 program. The company updated its FY2025 guidance, now projecting revenue of $1.550B-$1.585B and adjusted EPS of $6.60-$6.70, lower than previous estimates.

Lantheus Holdings (NASDAQ: LNTH) has announced a definitive agreement to sell its SPECT business to SHINE Technologies. The transaction includes the sale of diagnostic agents TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®, along with related manufacturing facilities in North Billerica, Massachusetts, and Canadian operations. The deal allows Lantheus to focus on its innovative PET radiodiagnostics and microbubbles portfolio while advancing its radiopharmaceutical pipeline.

The transaction terms include an upfront cash payment, a note convertible into SHINE preferred stock, and potential earnout milestones. This strategic move follows Lantheus' recent agreements to acquire Life Molecular Imaging and Evergreen Theragnostics. The deal is expected to close by year-end, subject to customary conditions.

Lantheus Holdings announced positive results for its Alzheimer's disease radiodiagnostic MK-6240, which successfully met co-primary endpoints in two pivotal studies. The F18-labeled tau PET radiodiagnostic demonstrated strong sensitivity and specificity in detecting tau pathology, a key marker of Alzheimer's disease.

The company plans to submit a New Drug Application (NDA) to the FDA in Q3 2025. MK-6240 targets aggregated tau protein in neurofibrillary tangles and complements Lantheus' existing beta amyloid PET imaging agent, NAV-4694, currently in Phase 3 development.

Market projections indicate the U.S. Alzheimer's Disease radiodiagnostic market could reach over 400,000 scans and $1.5 billion by 2030, driven by increasing disease prevalence, expanded treatment options, and broader PET imaging guidelines. Over 100 therapies targeting beta amyloid or tau are currently in clinical development.

Lantheus Holdings (NASDAQ: LNTH) has scheduled its first quarter 2025 earnings conference call and webcast for May 7, 2025, at 8:00 a.m. ET. The company will discuss its financial and operating results during this presentation.

Participants interested in joining the conference call or webcast can register through the investor relations website at https://investor.lantheus.com/news-events/calendar-of-events. Registration is recommended 15 minutes before the event to avoid delays. A replay will be made available approximately two hours after the webcast concludes and will remain accessible for at least 30 days on the same webpage.

Lantheus Holdings (NASDAQ: LNTH) has completed its acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company, as announced on January 28, 2025. The acquisition brings key assets to Lantheus including:

• OCTEVY™, a registrational-stage PET diagnostic imaging agent for neuroendocrine tumors, complementing Lantheus' therapeutic candidate PNT2003
• A portfolio of clinical and pre-clinical theranostic pairs
• Radioligand therapy manufacturing infrastructure
• A revenue-generating CDMO business

The strategic move strengthens Lantheus' position in the radiopharmaceutical sector by expanding its capabilities across development, manufacturing, and commercialization.

Lantheus Holdings (NASDAQ: LNTH) reported strong financial results for Q4 and full year 2024. The company achieved worldwide revenue of $391.1M in Q4 (+10.5% YoY) and $1.53B for full year 2024. PYLARIFY reached blockbuster status with over $1B in net sales, while Q4 sales grew 15.7% to $266.0M.

Q4 highlights include DEFINITY sales increase of 17.9% to $86.2M, operating income decrease of 17.2% to $113.9M, and adjusted EPS decline of 9% to $1.59. The company's cash position strengthened to $912.8M by year-end 2024.

Lantheus announced strategic acquisitions including Life Molecular Imaging and Evergreen Theragnostics, expected to close in H2 2025. These deals aim to expand the company's radiopharmaceutical portfolio and manufacturing capabilities. The company also initiated a $250M share repurchase program, with $100M already executed at an average price of $89.59.